Oncologist Lewis Silverman on Revlimid for Patients with Myelodysplastic Syndrome

Article

Lewis Silverman, an oncologist with Mount Sinai Medical Center, discusses a clinical trial involving Revlimid (lenalidomide) for patients with a type of myelodysplastic syndrome.

Lewis Silverman, an oncologist with Mount Sinai Medical Center, discusses a clinical trial involving Revlimid (lenalidomide) for patients with a type of myelodysplastic syndrome.

Revlimid is currently approved for patients with a specific type of MDS that contains a chromosomal abnormality called deletion 5q.

The phase 3 trial,which was reported at the 2014 American Society of Hematology, includes patients with MDS who do not have the chromosomal abnormality but have low-risk disease.

The purpose of the study was to find out if Revlimid could reduce the number of red blood cell transfusions needed by anemic (transfusion-dependent) patients with low- or intermediate-risk MDS without a deletion 5q chromosome abnormality.

Silverman says the study confirms that about a quarter of patients who do not have the deletion 5q abnormality can become transfusion independent, and the duration of treatment response is about eight or nine months.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey. If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key. “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained. READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Related Content
Illustration of a woman with a blonde pixie hairstyle.

Cancer Survivors Can Get Tired of Being Called ‘Strong’

April 27th 2024
Article

I must admit when people call us cancer survivors "strong," it's a double-edged sword.

Read More

Image of red blood cells.

Early Transfusions, Treatments May Improve Outcomes in Low-Risk MDS

April 25th 2024
Article

Receiving early transfusions and treatment to reduce transfusion dependency significantly improves survival and quality of life in low-risk MDS.

Read More

Illustration of a woman with short blonde hair and a toothy smile.

How COVID-19 Helped Me Cope Day to Day With Cancer

April 11th 2024
Article

I was surprised that COVID-19 taught me how to cope with the daily annoyances of cancer.

Read More

Image of red blood cells.

Elritercept Receives FDA Fast Track Designation for MDS Treatment

March 22nd 2024
Article

The novel treatment elritercept received a Fast Track designation from the FDA to treat anemia in patients with MDS.

Read More

Image of a patient holding an orange bottle of pills.

Blood Cancer Drug Decreases Levels of Anti-Fungal Medication

March 19th 2024
Article

Patients taking Tibsovo to treat MDS or AML may want to discuss the appropriate medications to treat and prevent infections, an expert said.

Read More

Image of the FDA's logo.

FDA Committee in Favor of Imetelstat for Transfusion-Dependent MDS

March 15th 2024
Article

The Oncologic Drug Advisory Committee voted that the benefits of imetelstat outweigh the risks for transfusion-dependent myelodysplastic syndrome and anemia.

Read More